Health Care [ 4/12 ] | Biotechnology [ 14/75 ]
NASDAQ | Common Stock
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.
The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial.
In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform.
The company was founded in 2005 and is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 25, 26 | -0.62 Decreased by -287.50% | -0.51 Decreased by -20.86% |
| Nov 10, 25 | -0.54 Decreased by -42.11% | -0.54 |
| Aug 11, 25 | -0.57 Decreased by -62.86% | -0.48 Decreased by -18.75% |
| May 12, 25 | -0.53 Decreased by -70.97% | -0.32 Decreased by -66.67% |
| Feb 26, 25 | -0.16 Decreased by -700.00% | -0.09 Decreased by -70.21% |
| Nov 12, 24 | -0.38 Decreased by -52.00% | -0.36 Decreased by -5.56% |
| Aug 7, 24 | -0.35 Decreased by -20.69% | -0.36 Increased by +2.78% |
| May 13, 24 | -0.31 Increased by 0.00% | -0.11 Decreased by -181.82% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 0.00 Decreased by -100.00% | -30.17 M Decreased by -323.95% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 25 | 0.00 Decreased by -100.00% | -24.57 M Decreased by -95.68% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by -100.00% | -25.91 M Decreased by -135.56% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by -100.00% | -24.39 M Decreased by -149.04% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 11.13 M Decreased by -7.92% | -7.12 M Decreased by -833.83% | Decreased by -63.94% Decreased by -914.17% |
| Sep 30, 24 | 2.26 M Decreased by -63.44% | -12.56 M Decreased by -96.49% | Decreased by -555.20% Decreased by -437.41% |
| Jun 30, 24 | 3.97 M Increased by +1.38% | -11.00 M Decreased by -49.32% | Decreased by -276.97% Decreased by -47.29% |
| Mar 31, 24 | 4.91 M Increased by +64.29% | -9.79 M Decreased by -26.08% | Decreased by -199.60% Increased by +23.26% |